Adam Grossman: Absolutely. I mean, look, patients advocate for themselves in 2023 if you’re a smart patient and if you’re somebody who wants to get better. What we see is that patients are out there advocating for themselves. Gary, if you haven’t seen the new additions to the ASCENIV website, there are two patient advocates who tell their story and they talk about how they — one patient talks about how their doctor said, hey, I learned about this drug at a conference and I think it might be right for you. The other patient said, I learned about this drug, went to my doctor and I said, don’t you think this is right for me? So I think that certainly is a big part of this. We have — look, we’re a smallish company, but we are spending more time marketing to patients.
We are working much more closely and in a much broader capacity with the patient advocacy groups Immune Deficiency Foundation, Jeffrey Modell Foundation, amongst others. And we think that that certainly is helping add to the growth for ASCENIV. What was the first part of your question?
Gary Nachman: Donors.
Adam Grossman: Oh, donors, yes, yes, yes. I mean, look, do we pay our donors more? I don’t know if donors are listening. I don’t think we are paying them that much more right now. There is a plethora of plasma donors out there today. Donor fees are coming down across the Board. Brian certainly can speak more specifically to that in a moment. But I’ve talked about this, I think in past calls, and it’s funny that you asked the question, Gary, because maybe I had a management team meeting with everybody at the company this week and we’re talking about how we’ve got testing up and running in-house here for RSV donor screening and that certainly is going to help expedite the accessioning of these donors, the identification of which donors in our collection center network have the highest levels of neutralizing antibodies to RSV in the panel of respiratory pathogens that we look for.
And what I can tell you is that part of our supply chain robustness in owning our own centers is we can choose which donors we’re collecting plasma from. So we’re not saying that our third-party providers have not been great. They’ve been fantastic. And we love you all, and we hope you keep selling us good, high quality plasma. But if you work for ADMA, I have more control over what you do, plain and simple. I don’t care about sending it to somebody else. I don’t care if it has to go into that box. I want it where I want it, and that’s what I want. So we can easily ensure that we get every single RSV high titer donor that we identify in testing. That is not something that I can say with our third-party vendors. We lose donors. Every unit of plasma that a donor that we’ve identified as an appropriate donor for an ASCENIV plasma pool, we have access to.
So this was part of our strategy, this was part of the philosophy was that, okay, if the drug does take off, if we do start selling tens of thousands of grams every month, if this is the way it is, and we need all this plasma, how are we going to really control, and it wasn’t just the need of the source plasma. It was also because we know folks like you are going to ask us these questions. So yes, we have full control over our plasma supply chain from a normal source perspective, but we also have full control over our supply chain from an RSV hyperimmune plasma perspective. And this coupled with the fact that we are testing in-house the initial screens, we think that that’s going to help us identify more donors and faster. We are continuing to work with our third-party laboratory.
We plan to keep that third-party laboratory continuing to test forever, because the one thing I’ve learned in my seat at ADMA Biologics is redundancy is the key to success. So even though we can do it better and more efficiently, we’re going to continue to keep the assay up and running to ensure the continuity of supply and plasma collection.
Brian Lenz: Just to add on a bit about the plasma centers, we’re very pleased with the exponential growth. It was just a few years ago back in 2020, when we embarked on a supply chain robustness initiative where we only had one center. Back in 2020, we had three centers that were collecting and one center that was FDA approved. Fast-forward to 2023, we now have 10 centers collecting with nine FDA approvals, and the last center we’re hoping to receive FDA approval by the end of the year. So again, we’re very pleased with the exponential growth. We’d like to thank our BioCenters employees for the ramp up and the expansion, as well as our donors who go and donate because we couldn’t do what we do without you.
Gary Nachman: Absolutely. Excellent. Thank you for all that detail. That was really helpful.
Adam Grossman: Thanks, Gary.
Operator: Thank you. This will conclude the Q&A portion of the conference. I would now like to turn the conference back to the CEO, Adam Grossman, for closing remarks.
Adam Grossman: Thanks, everybody. It’s been a hell of a journey to get here for those of you who’ve been here since the beginning, thanks for sticking around. For those of you who are joining us now for the first time, welcome. I really mean it when I say it to all my staff; I’m getting tons of texts here. You all matter. You all make a difference in the lives of all these patients. To all the shareholders, nice texts and messages that we’ve received. Thank you very much. There’s only one time in a company’s history that you can say that your first time net income positive. So this is the collaborative efforts of many, many people. Thanks for outing faith in mine, my father’s vision. It makes me a little bit emotional to think about it.
But look, we’re going to keep doing what we say. We’re going to keep under promising and over delivering, and donate some plasma, take your vaccines, wash your hands, use PURELL, keep the world a safe place. And thank you for everything that you do. We appreciate your time and commitment to ADMA Biologics. Have a good evening, everybody.
Operator: This concludes today’s conference call. Thank you all for participating. You may now disconnect and have a pleasant day.